Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell calculates more than 700,000 benchmarks daily covering approximately 98 percent of the investable market globally, 80 countries and more than 10,000 securities. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes. We are pleased to be joining the Russell Microcap Index and look forward to increased exposure to the investment community, said Neil K. Warma, President and Chief Executive Officer of Opexa. This listing provides an additional opportunity to generate interest in Opexa as we continue to make progress on our Abili-T clinical trial and leverage our T-cell immunotherapy platform. Members of the Russell Microcap Index are automatically included in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived … Continue reading →

PLEASED: Tom said he hopes a cannabis-based product will be available to people with MS soon THE partner of a right-to-die campaigner says moves to legalise cannabis treatment for MS sufferers will go a long way to improve their quality of life. Tom Curran, who has been outspoken in the past on the pain-relieving effect that cannabis had on his late partner Marie Fleming, said he is delighted the State is to legalise medicinal cannabis next month. During Maries long battle with multiple sclerosis, Tom grew cannabis to help her with her pain. He said not only did it help with her symptoms, but it also helped to counter some of the side effects of MS. Next month, Junior Health Minister Alex White will sign a ministerial order allowing the Irish Medicines Board and the National Centre for Pharmacoeconomics (NCPE) to assess the likely costs and how the medicine might be promoted. Hopefully, with the legal impediments removed, a cannabis-based medicinal product can soon be available to ease the symptoms of spasticity for people with MS, where other conservative treatments have failed, Minister White said. Sativex, an oral spray made by GW Pharmaceuticals, is credited with treating muscle spasticity in … Continue reading →

Published: Monday, 6/30/2014 - Updated: 10 seconds ago LAKE ERIE ALGAE BLOOMS BY STEPHEN GRUBER-MILLER BLADE STAFF WRITER Lake Eries annual algae blooms can carry harmful toxins into public drinking water treatment plants, but facilities arent specifically required to test for the toxins. To combat the toxins, many water treatment facilities along Lake Eries Western Basin, from Lorain, Ohio, to Monroe, are cooperating with the Ohio Environmental Protection Agency by testing voluntarily for microcystin, a toxin in microcystis, the lakes most prevalent form of harmful blue-green algae. Algal blooms are a result of high levels of phosphorous in the water attributed to runoff from agricultural fertilizer, manure, sewage overflows, and septic systems. The toxin can cause breathing problems, skin reactions, and liver damage, and large enough quantities can even be deadly. State code requires that public drinking water systems plan for at least 10 of the most likely emergencies and provide descriptions of response procedures and how to maintain service during those emergencies. But many plants do not list algal toxins among those common emergencies. They get to choose what emergencies to plan for, Dina Pierce, an Ohio EPA spokesman, said to explain why some plants have algae plans in … Continue reading →